Unlocking the Potential of Cell and Gene Therapy for All
Personalized cell and gene therapies (CGTs) offer pofential to address the world`s most challenging diseases. We are committed to helping to bring these advanced therapies to market effectively.

Bringing Advanced Therapies Within Reach
Providing advanced therapies to the patients who need them Is complex and expensive. The Orgenesls POCare Platform was designed to simplify this process with a unique approach to drug development and scale-up.

Our team has forged relationships within the blotech Industry and with top academla, research Institutes and hospitals to commercialize point of care therapies across the globe.

Orgenesis works to make therapies commercially accessible

An Ecosystem of Innovation
Our POCare Platform Is shaping a CGT ecosystem to lower costs, accelerate treatments to market and expand access for patients.

We have internal development and services centers and global partner locations where we leverage our expertise with highly scalable and cost-effective solutions to advance a pipeline of owned and partnered technologies for point of care production.

Working with us means immediate access to the know-how that has the potential to commercialize therapies and them to the patients who need them.

Making Cell & Gene Therapies a Reality

In 2019, there were over 1,000 cell and gene therapy related clinical trials ongoing globally. But most of these biotechnology companies and research institutes lack the expertise to scale their development and manufacturing operations to make them accessible and affordable.

We work to overcome existing challenges of CGT production with process development, manufacturing systems, logistics, and regulatory expertise.

Orgenesis Inc. products

POCare Platform

POCare - Therapies

POCare - Technology